Navigation Links
MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
Date:2/28/2008

MOUNTAIN VIEW, Calif., Feb. 28 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced financial results for the fourth quarter and year ended December 31, 2007.

The net loss for the fourth quarter and year ended December 31, 2007 was $14.9 million and $40.1 million, respectively, compared with $8.5 million and $25.8 million during the same periods in 2006. MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of December 31, 2007 of $95.0 million.

2007 Accomplishments

During 2007, MAP Pharmaceuticals' accomplishments included the following:

-- Successfully completed Phase 2 trial and presented positive results

for Unit Dose Budesonide (UDB), for the potential treatment of

pediatric asthma, at the World Asthma Meeting. In this randomized,

double-blind, placebo-controlled trial, UDB produced a statistically

significant reduction in nighttime and daytime composite symptom

scores vs. placebo for the low dose tested. Positive trends in Forced

Expiratory Volume in one second were seen in those patients old enough

to take the test. UDB was shown in the trial to be well tolerated and

there were no serious adverse events reported. In this trial,

complete nebulization of UDB using a standard nebulizer occurred in an

average of three to five minutes.

-- Successfully completed Phase 2 trial and presented positive results

for MAP0004, an orally inhaled formulation of dihydroergotamine, for

the potential treatment of migraine, at the American Headache Society

Meeting. In this randomized, double-blind, placebo-controlled trial,
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Four hospitals affiliated with the ... latest ranking of the country’s best hospitals by ... today and slated for publication in August, the U.S. ... (AGH), Forbes Hospital, Saint Vincent Hospital and West Penn ... specialties. , “There is no higher priority ...
(Date:7/23/2014)... Kathleen Doheny HealthDay Reporter ... surgery appears to have an additional side benefit -- ... to a new study. The study found that ... reported having incontinence prior to the procedure. After surgery, ... improved or disappeared, said study researcher Dr. Leslee Subak, ...
(Date:7/23/2014)... News) -- For patients infected with both HIV and ... both viruses, a small study suggests. Researchers said ... for people with the two diseases. "The ... an important role in the management of individuals with ... Kenneth Sherman, a professor of medicine at the University ...
(Date:7/23/2014)... BOSTON In a massive effort to catalog ... researchers at Dana-Farber Cancer Institute, have identified four ... other molecular abnormalities. They say the new classification ... therapies for the third-leading cancer killer worldwide. , ... of The Cancer Genome Atlas Research Network said ...
(Date:7/23/2014)... focused on the regions of the coding genome (exons) ... amino acids thus proteins. But just before each gene, ... the expression and activity of the adjacent gene. Until ... such DNA fragment in tumor development. , An ... with the group of Manel Esteller, Director of Epigenetics ...
Breaking Medicine News(10 mins):Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3Health News:HIV Meds May Also Help Control Hepatitis C, Study Finds 2Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3
... 10 Amedica Corporation, an,orthopedic implants company focused ... paper it presented on the in-vitro,testing and evaluation ... arthroplasty won the HAP Paul Award from the ... HAP Paul Award, which,was presented to Amedica at ...
... Shows Majority of Americans Would Like to See the United States ... ... a national bipartisan poll,commissioned by the US Coalition for Child Survival, ... cause of,child deaths in the world,s poorest countries. In reality, pneumonia,diarrhea, ...
... its 60th anniversary, the American Association for Cancer ... health disparities and minority cancer education. , AACEs ... Sheraton Birmingham Hotel, 2101 Richard Arrington Jr. Boulevard ... Minority and Underserved Populations. , The AACE meeting ...
... Ala., Oct. 10 Major financial implications are,at ... accurately record,the health conditions of patients that are ... the Centers for Medicare and Medicaid,Services (CMS). ... Group (DRG),assignment, including new methods for identifying patients ...
... 10 The American Medical,Student Association (AMSA), ... announced that a coalition representing the,majority of ... to pass the National Health Service Corps ... of 2007 (H.R. 2915). The NHSC ...
... YORK, Oct. 10 Buck Consultants, an ACS ... and benefits consulting firms,today announced the results of ... Buck,s study, "WORKING WELL: A Global Survey of ... 555 organizations,representing approximately 7 million employees. Such ...
Cached Medicine News:Health News:Amedica's Silicon Nitride Ceramic Bearing Technology Receives Prestigious HAP Paul Award for Use in Total Hip Arthroplasty 2Health News:Sixty Percent of Americans Cannot Name Top Killers of Kids 2Health News:Sixty Percent of Americans Cannot Name Top Killers of Kids 3Health News:US, European cancer educators gather in Alabama for meeting 2Health News:Use of Technology to Document Comorbid Conditions May Improve Reimbursement, Increase Documentation Accuracy Study Confirms 2Health News:Use of Technology to Document Comorbid Conditions May Improve Reimbursement, Increase Documentation Accuracy Study Confirms 3Health News:Coalition Urges Congress to Increase Funding for National Health Service Corps 2Health News:Coalition Urges Congress to Increase Funding for National Health Service Corps 3Health News:Buck Consultants Reports Wellness Programs Are Truly Global; Objectives Vary by Region 2Health News:Buck Consultants Reports Wellness Programs Are Truly Global; Objectives Vary by Region 3Health News:Buck Consultants Reports Wellness Programs Are Truly Global; Objectives Vary by Region 4
(Date:7/23/2014)... ROCHESTER, N.Y. , July 23, 2014 ... VSCP ), a leading provider of clinical trial ... , 48, has been named president and chief executive ... of Directors in August 2013 and has held the ... October 25, 2013. Dr. Charles E. ...
(Date:7/23/2014)... 23, 2014 Research and Markets ... in Consumer Healthcare by Application, Sensor Type & by ... 2020" report to their offering. ... an increasing momentum for consumer healthcare monitoring and sensing ... consumer healthcare will lessen the healthcare cost of the ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, ... in translational preclinical research, today unveiled their new logo ... the transformation of Surpass, corporate culture to one where ... customers. This press release comes on the heels of ... added to the Silicon Valley Team:  David Craig, a ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 2Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 3SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Sept. 30, 2011 Haemonetics Corporation (NYSE: ... quarter of its 2012 fiscal year on October 31, ... hold a webcast to discuss and answer questions about ... 31, 2011. Webcast Link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=4204617 ...
... Sept. 29, 2011 Boston Scientific Corporation (NYSE: ... ( NE ural C ardiac T her A ... a prospective, randomized, international clinical feasibility study designed to assess ... heart failure patients.  The study will evaluate 96 patients with ...
Cached Medicine Technology:Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 2Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 3Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 4
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With cast aluminum base • ...
... concave seats and large backrests with ... seats, backrests, armrests, and casters and ... for top performance in a variety ... clean room, static control, health care ...
... ergonomic chairs with concave seats and ... Select options like seats, backrests, armrests, ... the BE Series for top performance ... industry, education, laboratory, clean room, static ...
... seats and large backrests with lumbar support ... and casters and glides. • Choose the ... variety of environments including: industry, education, laboratory, ... office. • With cast aluminum base • ...
Medicine Products: